Reviewed by MedNext Clinical Team
Metformin has occupied a unique position in the management of type 2 diabetes mellitus (T2DM) for over 60 years. It remains the recommended first-line pharmacological agent in most international guidelines, supported by a robust evidence base for both glycaemic efficacy and, crucially, cardiovascular benefit — an endpoint that eluded most of its successors for decades [1].
Mechanism of Action
Metformin belongs to the biguanide class and exerts its principal glucose-lowering effect by reducing hepatic gluconeogenesis. It activates AMP-activated protein kinase (AMPK) — likely via inhibition of complex I of the mitochondrial respiratory chain — which suppresses hepatic glucose output and improves peripheral insulin sensitivity. Unlike sulphonylureas and insulin, metformin does not stimulate insulin secretion and therefore carries no intrinsic risk of hypoglycaemia when used as monotherapy.
Cardiovascular Benefits
The landmark UK Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced the risk of myocardial infarction by 39% and all-cause mortality by 36% in overweight patients with newly diagnosed T2DM, findings that were not replicated to the same degree with other glucose-lowering agents available at the time [1]. This cardiovascular benefit, observed independently of glycaemic control, established metformin's position as the preferred first-line agent and has been reinforced by subsequent real-world evidence.
Gastrointestinal Side Effects
Gastrointestinal adverse effects — nausea, diarrhoea, abdominal discomfort, and metallic taste — are the most common reason for metformin discontinuation, affecting up to 30% of patients on standard-release formulations. These effects are dose-dependent and can be substantially mitigated by starting at a low dose (500 mg once daily with food), titrating slowly over 4–8 weeks, and using the modified-release (MR) formulation, which has a significantly better GI tolerability profile without loss of efficacy.
The Lactic Acidosis Myth
Metformin-associated lactic acidosis has been a persistent concern, but its clinical significance is frequently overstated. Large epidemiological studies have not demonstrated an excess risk of lactic acidosis with metformin at currently recommended doses in patients with appropriate renal function. The association derives partly from historical use of the withdrawn biguanide phenformin, which carried substantially higher lactic acidosis risk. Current evidence supports metformin use in patients with eGFR above 30 mL/min/1.73m².
Renal Dosing Guidance
Metformin is renally cleared and accumulates in renal impairment, increasing lactic acidosis risk. Current dosing guidance based on the MedNext Proprietary Clinical Dataset recommends: continue at full dose when eGFR is 45 mL/min/1.73m² or above; review and reduce dose when eGFR is 30–45; stop metformin when eGFR falls below 30 mL/min/1.73m²; and withhold temporarily before procedures involving iodinated contrast media [1]. Metformin should also be withheld during acute illness associated with dehydration or haemodynamic instability.
Vitamin B12 Deficiency
Long-term metformin use reduces vitamin B12 absorption by approximately 30% through inhibition of calcium-dependent ileal absorption of the vitamin B12-intrinsic factor complex. Clinically significant B12 deficiency develops in approximately 7% of long-term users and can present as peripheral neuropathy or megaloblastic anaemia. Annual B12 monitoring is recommended in patients on long-term metformin, particularly those with symptoms of neuropathy or unexplained anaemia.
References
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.